According to the Financial Intelligence APP, Skye Bioscience (SKYE.US) saw its stock price soar 11% on Monday local time, thanks to the safety differences between its weight loss candidate nimacimab and novo-nordisk (NVO.US)'s monlunabant. Skye emphasized that its monoclonal antibody nimacimab did not show any neuro-psychiatric adverse events in Phase I studies, and preclinical studies showed minimal accumulation in the brain. Meanwhile, the Phase II clinical trial data for monlunabant released by novo-nordisk last Friday showed significant weight loss effects but with mild to moderate neuro-psychiatric and gastrointestinal side effects. Following the news, novo-nordisk's stock price declined.

It is understood that Skye is currently conducting Phase II studies on nimacimab for the treatment of obesity and evaluating the efficacy of the GLP-1/CB1 inhibitor combination. Mid-term weight loss data is expected to be announced in the second quarter of 2025, with topline data planned for release in the fourth quarter of 2025. It is worth noting that the GLP-1R agonist drug being evaluated in combination with nimacimab is novo-nordisk's Wegovy (semaglutide).

On Monday, novo-nordisk's stock price dropped by 3%, while Viking Therapeutics (VKTX.US), also dedicated to weight loss drug development, saw a 6% decline in its stock price. Meanwhile, Structure Therapeutics (GPCR.US) bucked the trend with an over 1% rise in its stock price, thanks to morgan stanley's positive review giving the company a shareholding rating for the first time.